Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 3/20 | 1.00 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.80 |
| ▸ | KDR | P35968 | 2/20 | 0.80 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.80 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.80 |
| ▸ | EGFR | P00533 | 1/20 | 0.80 |
| ▸ | CDK2 | P24941 | 1/20 | 0.80 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.80 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.80 |
| ▸ | AURKB | Q96GD4 | 16/20 | 0.79 |
| ▸ | AURKA | O14965 | 9/20 | 0.79 |
| ▸ | PTK6 | Q13882 | 2/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14507168 | 0.92 | LCK (0.85) | LCKCHEK1KDRRPS6KA3IRAK4 | |
| SCHEMBL14537097 | 0.91 | LCK (0.83) | LCKCHEK1KDRRPS6KA3IRAK4 | |
| SCHEMBL14536750 | 0.91 | LCK (0.83) | LCKCHEK1KDRRPS6KA3IRAK4 | |
| SCHEMBL13154943 | 0.89 | LCK (1.00) | LCKCHEK1KDRRPS6KA3IRAK4 | |
| SCHEMBL12473560 | 0.89 | AURKB (0.81) | LCKCHEK1KDRRPS6KA3IRAK4 | |
| SCHEMBL13954597 | 0.89 | LCK (0.80) | LCKCHEK1KDRRPS6KA3IRAK4 | |
| SCHEMBL14507452 | 0.88 | AURKB (1.00) | LCKCHEK1KDRRPS6KA3IRAK4 | |
| SCHEMBL13155437 | 0.88 | LCK (0.79) | LCKCHEK1KDRRPS6KA3IRAK4 | |
| SCHEMBL13155431 | 0.87 | AURKB (0.79) | LCKCHEK1KDRRPS6KA3IRAK4 | |
| SCHEMBL13155395 | 0.87 | LCK (0.77) | LCKCHEK1KDRRPS6KA3IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2217611-B1 | NOVEL MODULATORS OF CELL CYCLE CHECKPOINTS AND THEIR USE IN COMBINATION WITH CHECKPOINT KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2013-07-31 | — | — | EP | disclosed |
| US-20110183933-A1 | NOVEL MODULATORS OF CELL CYCLE CHECKPOINTS AND THEIR USE IN COMBINATION WITH CHECKPOINT KINASE INHIBITORS | MERCK SHARP & DOHME LLC | 2011-07-28 | — | — | US | disclosed |
| US-20100249030-A1 | ANTI-MITOTIC AGENT AND AURORA KINASE INHIBITOR COMBINATION AS ANTI-CANCER TREATMENT | SCHERING CORPORATION | 2010-09-30 | — | — | US | disclosed |
| US-20100249030-A1 | ANTI-MITOTIC AGENT AND AURORA KINASE INHIBITOR COMBINATION AS ANTI-CANCER TREATMENT | SCHERING CORPORATION | 2010-09-30 | — | — | US | disclosed |
| WO-2009017701-A2 | ANTI-MITOTIC AGENT AND AURORA KINASE INHIBITOR COMBINATION AS ANTI-CANCER TREATMENT | SCHERING CORPORATION (US) | 2009-02-05 | — | — | WO | disclosed |
| WO-2007058942-A2 | IMIDAZOPYRAZINES AS PROTEIN KINASE INHIBITORS | SCHERING CORPORATION (US) | 2007-05-24 | — | — | WO | disclosed |
| US-20070117804-A1 | Imidazopyrazines as protein kinase inhibitors | SCHERING CORPORATION | 2007-05-24 | — | — | US | disclosed |
| US-20070117804-A1 | Imidazopyrazines as protein kinase inhibitors | SCHERING CORPORATION | 2007-05-24 | — | — | US | disclosed |
| WO-2007056468-A1 | METHODS FOR INHIBITING PROTEIN KINASES | SCHERING CORPORATION (US) | 2007-05-18 | — | — | WO | disclosed |
| US-20070105864-A1 | Methods for inhibiting protein kinases | SCHERING CORPORATION | 2007-05-10 | — | — | US | disclosed |
| US-20070105864-A1 | Methods for inhibiting protein kinases | SCHERING CORPORATION | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110183933-A1 | NOVEL MODULATORS OF CELL CYCLE CHECKPOINTS AND THEIR USE IN COMBINATION WITH CHECKPOINT KINASE INHIBITORS | CDC25C, CHEK1, CDC25A | LCK 179/4885CHEK1 2/4885KDR 1409/4885 |
| US-20100249030-A1 | ANTI-MITOTIC AGENT AND AURORA KINASE INHIBITOR COMBINATION AS ANTI-CANCER TREATMENT | AURKC, AURKA, AURKB | LCK 732/4885CHEK1 61/4885KDR 4451/4885 |
| US-20070117804-A1 | Imidazopyrazines as protein kinase inhibitors | CHEK1, CHEK2, CDKN1A | LCK 15/4885CHEK1 1/4885KDR 1998/4885 |
| US-20070105864-A1 | Methods for inhibiting protein kinases | PIM1, PIM2, PIM3 | LCK 88/4885CHEK1 27/4885KDR 2094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.